James W. Vardiman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
James W. Vardiman has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Richard A. Larson
University of Chicago, Chicago, IL
2 shared publications Anant Shah
Department of Pathology, University of Chicago, Chicago, IL
1 shared publicationAndrew J. Carroll
1 shared publicationAnna Porwit
Department of Pathology, Karolinska University Hospital, Stockholm, Sweden
1 shared publicationAyalew Tefferi
Division of Hematology, Mayo Clinic, Rochester, MN; and
1 shared publicationClara D. Bloomfield
Comprehensive Cancer Center, The Ohio State University, Columbus
1 shared publication
Latest Publications
- Open Access
- 1 July 2015
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 144 (1) , 29-43
Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Objectives:. Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) is a heterogeneous disorder defined by morphologic, genetic, or clini
- 1 July 2015
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 144 (1) , 29-43
Open AccessAcute Myeloid Leukemia With Myelodysplasia-Related Changes
Objectives:. Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) is a heterogeneous disorder defined by morphologic, genetic, or clini
- 24 April 2014
- Published by American Society of Hematology in Blood
- Vol. 123 (17) , 2742-2743
PLZF staining identifies peripheral T-cell lymphomas derived from innate-like T-cells with TRAV1-2-TRAJ33 TCR-α rearrangement
- 24 April 2014
- Published by American Society of Hematology in Blood
- Vol. 123 (17) , 2742-2743
PLZF staining identifies peripheral T-cell lymphomas derived from innate-like T-cells with TRAV1-2-TRAJ33 TCR-α rearrangement
- 1 December 2012
- Published by Elsevier in Leukemia Research
- Vol. 36 (12) , 1453-1458
The classification of MDS: From FAB to WHO and beyond
- 1 December 2012
- Published by Elsevier in Leukemia Research
- Vol. 36 (12) , 1453-1458
The classification of MDS: From FAB to WHO and beyond
- Open Access
- 10 December 2011
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2011 (1) , 250-256
World Health Organization Classification, Evaluation, and Genetics of the Myeloproliferative Neoplasm Variants
There is no single category in the fourth edition (2008) of the World Health Organization (WHO) classification of myeloid neoplasms that encompasses all of the diseases referred to by some authors as the myeloproliferative neoplasm (MPN) “variants.” Instead, they are considered as distinct entities and are distributed among various subgroups of myeloid neoplasms in the classification scheme. These relatively uncommon neoplasms do not meet the criteria for any so-called “classical” MPN (chronic myelogenous leukemia, polycythemia vera, primary myelofibrosis, or essential thrombocythemia) and, although some exhibit myelodysplasia, none meets the criteria for any myelodysplastic syndrome (MDS). They are a diverse group of neoplasms ranging from fairly well-characterized disorders such as chronic myelomonocytic leukemia to rare and thus poorly characterized disorders such as chronic neutrophilic leukemia. Recently, however, there has been a surge of information regarding the genetic infrastructure of neoplastic cells in the MPN variants, allowing some to be molecularly defined. Nevertheless, in most cases, correlation of clinical, genetic, and morphologic findings is required for diagnosis and classification. The fourth edition of the WHO classification provides a framework to incorporate those neoplasms in which a genetic abnormality is a major defining criterion of the disease, such as those associated with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1, as well as for those in which no specific genetic defect has yet been discovered and which remain clinically and pathologically defined. An understanding of the clinical, morphologic, and genetic features of the MPN variants will facilitate their diagnosis.
- 10 December 2011
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2011 (1) , 250-256
Open AccessWorld Health Organization Classification, Evaluation, and Genetics of the Myeloproliferative Neoplasm Variants
There is no single category in the fourth edition (2008) of the World Health Organization (WHO) classification of myeloid neoplasms that encompasses all of the diseases referred to by some authors as the myeloproliferative neoplasm (MPN) “variants.” Instead, they are considered as distinct entities and are distributed among various subgroups of myeloid neoplasms in the classification scheme. These relatively uncommon neoplasms do not meet the criteria for any so-called “classical” MPN (chronic myelogenous leukemia, polycythemia vera, primary myelofibrosis, or essential thrombocythemia) and, although some exhibit myelodysplasia, none meets the criteria for any myelodysplastic syndrome (MDS). They are a diverse group of neoplasms ranging from fairly well-characterized disorders such as chronic myelomonocytic leukemia to rare and thus poorly characterized disorders such as chronic neutrophilic leukemia. Recently, however, there has been a surge of information regarding the genetic infrastructure of neoplastic cells in the MPN variants, allowing some to be molecularly defined. Nevertheless, in most cases, correlation of clinical, genetic, and morphologic findings is required for diagnosis and classification. The fourth edition of the WHO classification provides a framework to incorporate those neoplasms in which a genetic abnormality is a major defining criterion of the disease, such as those associated with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1, as well as for those in which no specific genetic defect has yet been discovered and which remain clinically and pathologically defined. An understanding of the clinical, morphologic, and genetic features of the MPN variants will facilitate their diagnosis.
- 1 March 2010
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 184 (1-2) , 16-20
The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: An overview with emphasis on the myeloid neoplasms
- 1 March 2010
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 184 (1-2) , 16-20
The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: An overview with emphasis on the myeloid neoplasms
- Top Cited Papers
- 30 July 2009
- Published by American Society of Hematology in Blood
- Vol. 114 (5) , 937-951
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
Recently the World Health Organization (WHO), in collaboration with the European Association for Haematopathology and the Society for Hematopathology, published a revised and updated edition of the WHO Classification of Tumors of the Hematopoietic and Lymphoid Tissues. The 4th edition of the WHO classification incorporates new information that has emerged from scientific and clinical studies in the interval since the publication of the 3rd edition in 2001, and includes new criteria for the recognition of some previously described neoplasms as well as clarification and refinement of the defining criteria for others. It also adds entities—some defined principally by genetic features—that have only recently been characterized. In this paper, the classification of myeloid neoplasms and acute leukemia is highlighted with the aim of familiarizing hematologists, clinical scientists, and hematopathologists not only with the major changes in the classification but also with the rationale for those changes.
- 30 July 2009
- Published by American Society of Hematology in Blood
- Vol. 114 (5) , 937-951
Top Cited PapersThe 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
Recently the World Health Organization (WHO), in collaboration with the European Association for Haematopathology and the Society for Hematopathology, published a revised and updated edition of the WHO Classification of Tumors of the Hematopoietic and Lymphoid Tissues. The 4th edition of the WHO classification incorporates new information that has emerged from scientific and clinical studies in the interval since the publication of the 3rd edition in 2001, and includes new criteria for the recognition of some previously described neoplasms as well as clarification and refinement of the defining criteria for others. It also adds entities—some defined principally by genetic features—that have only recently been characterized. In this paper, the classification of myeloid neoplasms and acute leukemia is highlighted with the aim of familiarizing hematologists, clinical scientists, and hematopathologists not only with the major changes in the classification but also with the rationale for those changes.
- Open Access
- 1 January 2006
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2006 (1) , 199-204
Hematopathological Concepts and Controversies in the Diagnosis and Classification of Myelodysplastic Syndromes
Although the diagnosis and classification of most cases of the myelodysplastic syndromes (MDS) is usually accomplished without difficulty, a minority of cases may pose diagnostic problems. In many cases the diagnostic dilemma can be solved by adhering to basic guidelines recommended for evaluation of patients suspected of having MDS, and in particular to the quality of the blood and bone marrow specimens submitted for morphologic, immunophenotypic and genetic studies. In other cases, such as patients who have hypocellular MDS or MDS with fibrosis, the criteria for making a diagnosis may be difficult if not impossible to apply, and in still others the diagnostic uncertainty is because the minimal criteria necessary to establish the diagnosis of MDS are not always clearly stated. In this review, some of these diagnostic problems are addressed and some general guidelines for resolving them are suggested. In addition, data are presented that illustrate that the WHO classification offers a valuable tool in the diagnosis and classification of MDS.
- 1 January 2006
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2006 (1) , 199-204
Open AccessHematopathological Concepts and Controversies in the Diagnosis and Classification of Myelodysplastic Syndromes
Although the diagnosis and classification of most cases of the myelodysplastic syndromes (MDS) is usually accomplished without difficulty, a minority of cases may pose diagnostic problems. In many cases the diagnostic dilemma can be solved by adhering to basic guidelines recommended for evaluation of patients suspected of having MDS, and in particular to the quality of the blood and bone marrow specimens submitted for morphologic, immunophenotypic and genetic studies. In other cases, such as patients who have hypocellular MDS or MDS with fibrosis, the criteria for making a diagnosis may be difficult if not impossible to apply, and in still others the diagnostic uncertainty is because the minimal criteria necessary to establish the diagnosis of MDS are not always clearly stated. In this review, some of these diagnostic problems are addressed and some general guidelines for resolving them are suggested. In addition, data are presented that illustrate that the WHO classification offers a valuable tool in the diagnosis and classification of MDS.
- 1 November 2002
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 21 (5) , 1041-1051
Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461
Isolated trisomy is a relatively common cytogenetic abnormality in acute myeloid leukemia (AML), but with uncertain prognostic significance. We studied a large cohort of newly diagnosed de novo AML patients karyotyped on CALGB 8461 from 1984-1999, where trisomy was the sole abnormality. The common isolated trisomies (ITC), +8, +11, +13 and +21, comprised 90% of all sole trisomies. The outcome of 101 ITC patients was compared to that of 976 with normal and cytogenetics. The overall survival (OS) for ITC patients was unsatisfactory with 10% [95% confidence interval (CI), 3-17%] alive at 5 years. Repeated cycles of I/HDAC intensification did not improve outcome. However, SCT significantly improved relapse-free survival (RFS). Among ITC patients <60 years in first remission, only 1 of 7 receiving SCT relapsed, compared to 16 of 19 patients treated with chemotherapy only. The prognosis of ITC was dependent on SCT. For non-transplanted patients, the 5-year OS for ITC was 5% (95% CI, 0-11%), compared to 20% (95% CI, 16-23%) for 640 normal cytogenetics patients. ITC was an independent adverse prognostic factor for OS in non-transplanted patients. In those receiving SCT, however, the 5-year OS for ITC patients (69%, 95% CI, 32-100%) was not different to that of transplanted normal cytogenetics patients (60%, 95% CI, 38-81%). We conclude that in de novo adult AML patients not receiving SCT, ITC appears to independently predict a poor outcome that may be improved with SCT in first remission. Prospective studies are required to confirm this hypothesis.
- 1 November 2002
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 21 (5) , 1041-1051
Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461
Isolated trisomy is a relatively common cytogenetic abnormality in acute myeloid leukemia (AML), but with uncertain prognostic significance. We studied a large cohort of newly diagnosed de novo AML patients karyotyped on CALGB 8461 from 1984-1999, where trisomy was the sole abnormality. The common isolated trisomies (ITC), +8, +11, +13 and +21, comprised 90% of all sole trisomies. The outcome of 101 ITC patients was compared to that of 976 with normal and cytogenetics. The overall survival (OS) for ITC patients was unsatisfactory with 10% [95% confidence interval (CI), 3-17%] alive at 5 years. Repeated cycles of I/HDAC intensification did not improve outcome. However, SCT significantly improved relapse-free survival (RFS). Among ITC patients <60 years in first remission, only 1 of 7 receiving SCT relapsed, compared to 16 of 19 patients treated with chemotherapy only. The prognosis of ITC was dependent on SCT. For non-transplanted patients, the 5-year OS for ITC was 5% (95% CI, 0-11%), compared to 20% (95% CI, 16-23%) for 640 normal cytogenetics patients. ITC was an independent adverse prognostic factor for OS in non-transplanted patients. In those receiving SCT, however, the 5-year OS for ITC patients (69%, 95% CI, 32-100%) was not different to that of transplanted normal cytogenetics patients (60%, 95% CI, 38-81%). We conclude that in de novo adult AML patients not receiving SCT, ITC appears to independently predict a poor outcome that may be improved with SCT in first remission. Prospective studies are required to confirm this hypothesis.
- 1 December 1996
- Published by JSTOR in Environmental Health Perspectives
- Vol. 104, 1303
Myeloid Leukemia after Hematotoxins
One of the most serious consequences of cancer therapy is the development of a second cancer, especially leukemia. Several distinct subsets of therapy-related l...
- 1 December 1996
- Published by JSTOR in Environmental Health Perspectives
- Vol. 104, 1303
Myeloid Leukemia after Hematotoxins
One of the most serious consequences of cancer therapy is the development of a second cancer, especially leukemia. Several distinct subsets of therapy-related l...